Compare Becton Dickinson and Co (BDX) vs TJX Companies Inc (TJX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Becton Dickinson and Co vs TJX Companies Inc — how do they compare? Becton Dickinson and Co trades at $154.29 (market cap $41.51B), while TJX Companies Inc trades at $150.35 (market cap $166.08B). The key difference: TJX Companies Inc is far larger — about 4× Becton Dickinson and Co's market cap, and Becton Dickinson and Co pays the higher dividend (2.79%). Which is the better fit depends on your goals.
| BDX | TJX | |
|---|---|---|
Market Cap | $41.51B | $166.08B |
Sector | Health | Consumer Cyclical |
52-Week High | $185.39 | $168.41 |
52-Week Low | $135.49 | $121.35 |
Enterprise Value | $57.97B | $174.68B |
Dividend Yield | 2.79% | 1.28% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BDX trades at $153.83, up 1.24% today, with technical indicators showing a neutral to bullish bias. The company has consistently beaten earnings estimates in recent quarters, with Q1 2026 EPS of $2.90 exceeding expectations. Revenue growth remains steady, reaching $21.84B in 2025, though net margins have compressed to 5.12%. Recent news highlights BDX's innovation in medical technology and positive analyst sentiment.
The outlook for BDX appears balanced. Upside potential exists from continued earnings beats and strategic positioning in growing healthcare segments like GLP-1 drug support equipment. However, risks include margin pressure, elevated debt levels, and cautious hospital spending. The consensus price target of $173.40 suggests moderate upside from current levels.
TJX trades at $150.53, down 0.54% today, with strong fundamentals including 8.63% net margin and 61.25% ROE. Recent quarters show consistent earnings beats, with Q1 2026 EPS of $1.19 surpassing the $1.02 estimate. Technical indicators signal near-term bearish pressure, but analyst consensus remains overwhelmingly bullish with an $181.80 price target. The company maintains robust cash flow from operations at $6.12B in 2025, supporting dividend payments and expansion plans.
Outlook is positive due to earnings momentum and international growth, but risks include valuation premiums (P/E 29.29) and consumer spending sensitivity. The stock offers growth potential if execution continues, though technical weakness may persist short-term.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Becton Dickinson and Co
Becton, Dickinson is the world's largest manufacturer and distributor of medical surgical products, such as needles, syringes, and sharps-disposal units. The company also manufactures diagnostic instruments and reagents, as well as flow cytometry and cell-imaging systems. BD Interventional (largely the former Bard business) accounts for 23% of revenue. International revenue accounts for 44% of the company's business.
Read more on BDX →About TJX Companies Inc
TJX is a leading off-price retailer of apparel, home fashions, and other merchandise. It sells a variety of branded goods, opportunistically buying inventory from a network of over 21,000 vendors worldwide. TJX targets undercutting conventional retailers' regular prices by 20%-60%, capitalizing on a flexible merchandising network, relatively low-frills stores, and a treasure-hunt shopping experience to drive margins and inventory turnover. TJX derived 79% of fiscal 2022 revenue from the United States, with 11% from Europe (mostly the United Kingdom and Germany), 9% from Canada, and the remainder from Australia. The company operated 4,689 stores at the end of fiscal 2022 under the T.J. Maxx, T.K. Maxx, Marshalls, HomeGoods, Winners, Homesense, Winners, and Sierra banners.
Read more on TJX →
